Home
Storia in 1 fonti
VIDEO: Alpha-emitting radioantibody lowers PSA in castration-resistant prostate cancer
CHICAGO — In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting radioantibody for patients with metastatic castration-resistant prostate cancer. Treatment effects also included a decline in prostate-specific antigen. Findings from the study, which assessed the safety and efficacy of Ac-225 rosopatamab tetraxetan (CONV01-alpha,
Raccontata da
healio.com
Timeline cronologica
- ·
VIDEO: ADT break may help therapy responders in metastatic prostate cancer
CHICAGO — In this video, Atish D. Choudhury, MD, PhD, discusses a study of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer…
- ·
VIDEO: Data support further study of radiopharmaceuticals in metastatic prostate cancer
CHICAGO — In this video, Pedro C. Barata, MD, MSc, FACP, discusses preliminary safety, dosimetry and pharmacokinetic results from the first part of the phase 3 ProstACT Global…
- ·
VIDEO: Alpha-emitting radioantibody lowers PSA in castration-resistant prostate cancer
CHICAGO — In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting radioantibody for patients with metastatic…